Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-healing Wound Management: A Phase II Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Utilizing wound healing trajectory analysis, patient-reported pain and QOL assessment, quantitative bacteriology, and inflammatory infiltrate quantification, an improvement in wound healing will be observed on a cellular, histomorphological and clinical level in the presence of a bioelectric dressing applied in conjunction with SOC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of a Bioelectric Dressing Used With Negative Pressure Wound Therapy to Treat Diabetic and Pressure Ulcers

NCT01022216

Wound Healing

COMPLETED PHASE2

Treatment of Chronic Wounds With Cold Plasma -Plasma Care® vs. Placebo

NCT07050667

Hard to Heal Wounds Infected Wound

COMPLETED NA

An Evaluation of a Fibrillar Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds

NCT03723577

Wound

WITHDRAWN NA

ECM and Blood Components for Wound Healing

NCT01909908

Ulcer Venous Ulcer Foot Ulcer, Diabetic

TERMINATED NA

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426

Diabetic Foot Ulcer Foot

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PROCELLERA Antimicrobial Wound Dressing is considered a non-interactive wound dressing containing silver and zinc, classification product code MGP. Non-interactive wound dressings are considered by FDA to be non-significant risk, as per their Investigational Device Exemptions Manual (publication FDA 96-4159).

Procellera is FDA cleared under K081977 for professional use as a wound dressing for partial and full-thickness wounds.

Selection of Subjects

Type of the Subject Population

* At least 18 years old
* Male or female
* All ethnic groups

As a military-civilian cooperative Phase II prospective randomized trial, the study population will include chronic wound patients from both military and civilian backgrounds.

As incidence of complex non-healing wounds remains high in both military and civilian hospital settings, it is estimated that recruitment rate will be sufficiently rapid at each research site. While unanticipated delays (e.g. slow accrual) may occur, the limited patient population and length of time allotted for the clinical study (2 years) is assumed to offset any delays. A total of 60 participants will be enrolled studywide to obtain 50 evaluable participants from both sites combined. Up to 16 patients will be screened each day. A consecutive series of patients who meet the following inclusion/exclusion criteria and agree to participate will be recruited.

Inclusion and Exclusion Criteria

1. Inclusion Criteria \> 18 years of age or older, male or female

* Female subject not pregnant - pregnancy excluded by HCG (urine or serum) or by history (tubal ligation, hysterectomy, or menopause).
* Have a non-healing external wound at any location of the body of ≥90 days duration that is (10-50 cm2) at initial screening and does not exceed 3 cm in depth.
* May have a wound requiring Negative Pressure Wound Therapy in conjunction with standard of care wound treatment.
* Subject is able to apply study dressing to his/her wound, or have a reliable and capable caregiver to do it.
* Subjects will have adequate blood flow to the wound as defined by Skin Perfusion Pressure (SPP)47-49 of \>30mmHg recorded over intact epidermis near the open wound margin.
* Subjects with arterial repairs having adequate blood flow to the wound as defined by Skin Perfusion Pressure (SPP) of \>30mmHg recorded over intact epidermis near the open wound margin.
* Absence of clinical signs of infection (such as fever; malodorous wound exudate; increasing wound pain, drainage, erythema, friable granulation tissue and or edema).
* Participant agrees to participate in follow-up evaluations.
* Participant must be able to read and understand informed consent, and signs the informed consent.
2. Exclusion Criteria

* Less than 18 years of age.
* Pregnant or lactating woman.
* Have undergone treatment with systemic corticosteroid or immunosuppressive therapy in the past 2 months.
* Currently undergoing dialysis for renal failure.
* Subject has wounds resulting from electrical burn, arterial insufficiency, chemical or radiation insult.
* Subject has wounds with exposed bone, ligament, nerve, artery and/or tendon.
* Active or previous (within 60 days prior to the study screening visit) chemotherapy.
* Active or previous (within 60 days prior to the study screening visit) radiation to the affected wound area to be treated by study device or standard of care.
* Physical or mental disability or geographical concerns (residence not within reasonable travel distance) that would hamper compliance with required study visits.
* The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including application of bioelectric dressings, standard-of-care self-care requirements, and all study-related follow up visit requirements.
* History of infection with Human Immunodeficiency Virus or other immunodeficiency disorders.
* Heterotopic ossification underlying the wound based upon previous imaging or historical information from the subject's chart.
* Severe anemia - Hgb \< 7 g/dl (males) or \< 6.5 (females) or coagulopathy (INR \> 1.7).
* Severe malnutrition (Albumin \< 3.0 gm/dl; \> 10% weight loss in preceding 6 weeks).
* Allergy to silver or zinc.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-healing Soft Tissue Wounds

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bioelectric Dressing

SOC + Bioelectric Dressing

Group Type ACTIVE_COMPARATOR

Procellera

Intervention Type DRUG

PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.

SOC

Standard of Care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Procellera

PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bioelectric Dressing

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\> 18 years of age or older, male or female

* Female subject not pregnant - pregnancy excluded by HCG (urine or serum) or by history (tubal ligation, hysterectomy, or menopause).
* Have a non-healing external wound at any location of the body of ≥90 days duration that is (10-50 cm2) at initial screening and does not exceed 3 cm in depth.
* May have a wound requiring Negative Pressure Wound Therapy in conjunction with standard of care wound treatment.
* Subject is able to apply study dressing to his/her wound, or have a reliable and capable caregiver to do it.
* Subjects will have adequate blood flow to the wound as defined by Skin Perfusion Pressure (SPP)47-49 of \>30mmHg recorded over intact epidermis near the open wound margin.
* Subjects with arterial repairs having adequate blood flow to the wound as defined by Skin Perfusion Pressure (SPP) of \>30mmHg recorded over intact epidermis near the open wound margin.
* Absence of clinical signs of infection (such as fever; malodorous wound exudate; increasing wound pain, drainage, erythema, friable granulation tissue and or edema).
* Participant agrees to participate in follow-up evaluations.
* Participant must be able to read and understand informed consent, and signs the informed consent.

Exclusion Criteria

* Less than 18 years of age.
* Pregnant or lactating woman.
* Have undergone treatment with systemic corticosteroid or immunosuppressive therapy in the past 2 months.
* Currently undergoing dialysis for renal failure.
* Subject has wounds resulting from electrical burn, arterial insufficiency, chemical or radiation insult.
* Subject has wounds with exposed bone, ligament, nerve, artery and/or tendon.
* Active or previous (within 60 days prior to the study screening visit) chemotherapy.
* Active or previous (within 60 days prior to the study screening visit) radiation to the affected wound area to be treated by study device or standard of care.
* Physical or mental disability or geographical concerns (residence not within reasonable travel distance) that would hamper compliance with required study visits.
* The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including application of bioelectric dressings, standard-of-care self-care requirements, and all study-related follow up visit requirements.
* History of infection with Human Immunodeficiency Virus or other immunodeficiency disorders.
* Heterotopic ossification underlying the wound based upon previous imaging or historical information from the subject's chart.
* Severe anemia - Hgb \< 7 g/dl (males) or \< 6.5 (females) or coagulopathy (INR \> 1.7).
* Severe malnutrition (Albumin \< 3.0 gm/dl; \> 10% weight loss in preceding 6 weeks).
* Allergy to silver or zinc.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No